Page last updated: 2024-12-05

laudanosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Laudanosine is a naturally occurring alkaloid found in various plants, including opium poppy (Papaver somniferum), and is structurally related to morphine. It is a quaternary ammonium compound with a complex polycyclic structure. Laudanosine has been reported to exhibit a variety of pharmacological effects, including anticholinergic, anticonvulsant, and anti-inflammatory properties. The mechanism of action of laudanosine is complex and not fully understood. Research suggests that it may act as a non-competitive inhibitor of acetylcholine esterase, a key enzyme involved in cholinergic neurotransmission. Laudanosine has also been shown to interact with various receptors, including serotonin, dopamine, and opioid receptors. However, due to its relatively low potency and potential toxicity, it is not currently used therapeutically. Nonetheless, its pharmacological properties make it a valuable research tool for studying the complexities of neurotransmission and related disorders. Furthermore, its unique chemical structure and biological activity have spurred interest in exploring its potential as a lead compound for the development of novel therapeutic agents.'

laudanosine: opium alkaloid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15548
CHEMBL ID1407
CHEBI ID91599
SCHEMBL ID466529
MeSH IDM0041746

Synonyms (99)

Synonym
MLS002634637
1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline
BRD-A24817035-001-05-4
NSC35045 ,
nsc-35045
KBIO1_001128
DIVK1C_006184
(+-)-laudanosine
ai3-61890
nsc 94267
einecs 216-923-9
isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, (+-)-
(+-)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinoline
(1)-1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinoline
isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratryl-, (+-)-
isoquinoline,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratryl-
veraisoquin
nsc-331268
isoquinoline,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-
20412-65-1
nsc331268
smr000064381
MLS000060551
SPECTRUM_000863
SPECTRUM5_001625
PRESTWICK3_000591
laudanosine (r,s)
1699-51-0
PRESTWICK_292
BSPBIO_001724
BSPBIO_000462
isoquinoline,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, (.+-.)-
isoquinoline,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratryl-, (.+-.)-
nsc-94267
(.+-.)-laudanosine
nsc94267
dl-laudanosine
BPBIO1_000510
OPREA1_379167
AB00052572
laudanosine
PRESTWICK2_000591
NCGC00142367-01
KBIO3_000864
KBIO2_006479
KBIO2_001343
KBIOGR_001488
KBIO2_003911
KBIOSS_001343
SPECTRUM2_000663
SPECTRUM3_000112
SPBIO_002681
PRESTWICK1_000591
SPECTRUM4_000934
PRESTWICK0_000591
SPECPLUS_000088
SPBIO_000725
(r,s)-laudanosine
L-1400
dl-laudanosine, free base
1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline
AKOS001094404
CHEMBL1407
HMS1569H04
HMS2096H04
HMS2271K11
CCG-38566
NCGC00017301-02
1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoqu inoline
FT-0670745
FT-0625478
AB00052572-12
AKOS022144164
dl-laudanosin
SCHEMBL466529
3-cyclohex-1-enyl-acrylicacid
(.+/-.)-laudanosine
isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, (.+/-.)-
KGPAYJZAMGEDIQ-UHFFFAOYSA-N
isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratryl-, (.+/-.)-
(.+/-.)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinoline
mfcd00006910
CHEBI:91599
5',8-dimethoxylaudanosine hydrochloride
A900016
Q27163429
AS-37336
1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline
HY-122489
EX-A3381
STL570293
CS-0085743
A937069
bdbm50270376
(r)-1-(3',4'-dimethoxybenzyl)-2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline
EN300-180011
DTXSID00871873
isoquinoline,1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, (1r)-
Z57474215

Research Excerpts

Overview

Laudanosine, which is a degradation product of atracurium, is a convulsant drug in the rat. Laudanosin is a metabolite of the neuromuscular-blocking drugs atracura and cisatracura.

ExcerptReferenceRelevance
"Laudanosine is a metabolite of the neuromuscular-blocking drugs atracurium and cisatracurium with potentially toxic systemic effects. "( Laudanosine, an atracurium and cisatracurium metabolite.
Fodale, V; Santamaria, LB, 2002
)
3.2
"Laudanosine, which is a degradation product of atracurium, is a convulsant drug in the rat. "( Convulsive effects and pharmacokinetics of laudanosine in the rat.
Crul, JF; Reekers-Ketting, J; Scheepstra, GL; van de Pol, F; Vree, TB, 1986
)
1.98

Actions

ExcerptReferenceRelevance
"D,L-Laudanosine failed to inhibit the binding of [3H]flunitrazepam to central benzodiazepine receptors in the cerebral cortex, the binding of [3H]PK 11195 to peripheral benzodiazepine binding sites in the cerebral cortex and kidney, the binding of [3H]Ro 5-4864 to peripheral benzodiazepine binding sites in the kidney, or the binding of [3H]quinuclidinyl benzilate to muscarinic receptors in the cerebral cortex."( Laudanosine does not displace receptor-specific ligands from the benzodiazepinergic or muscarinic receptors.
Gavish, M; Katz, Y, 1989
)
2.2

Pharmacokinetics

The plasma pharmacokinetic profiles of atracurium and its derivatives, laudanosine and monoquaternary alcohol, were studied in six patients with renal failure. Renal failure was defined as a creatinine clearance of less than 5 ml/min.

ExcerptReferenceRelevance
"A pharmacokinetic model was designed to describe simultaneously the plasma concentrations of atracurium and its metabolite laudanosine."( Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine.
Banoub, M; Nigrovic, V, 1992
)
0.72
" Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean ( +/- SD) terminal half-life (176 +/- 84 and 516 +/- 262 minutes for patients with normal and impaired renal function, respectively)."( Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function.
Agoston, S; Vandenbrom, RH; Wierda, JM, 1990
)
0.47
" The elimination half-life (T1/2 beta) of atracurium was significantly longer in the elderly group (23."( Pharmacokinetics of atracurium and laudanosine in the elderly.
Hunter, JM; Kent, AP; Parker, CJ, 1989
)
0.55
"The pharmacokinetic profile of atracurium was studied in normal patients and in patients with renal failure, renal-hepatic failure, or hepatic disease."( Pharmacokinetics of atracurium and its metabolites.
Ward, S; Weatherley, BC, 1986
)
0.27
" The plasma concentrations of atracurium for each patient were fitted to a two-compartment pharmacokinetic model."( The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure.
Canfell, C; Castagnoli, K; Fahey, MR; Fisher, DM; Hennis, PJ; Miller, RD; Rupp, SM; Sharma, M, 1984
)
0.27
" A two-compartment model was fitted to the 51W89 plasma concentration data using the NONMEM program, to estimate pharmacokinetic variables and to determine the influence of renal failure, age, weight and sex."( Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure.
Boyd, AH; Eastwood, NB; Hunter, JM; Parker, CJ, 1995
)
0.52
" The elimination half-life of 51W89 was significantly longer in renal failure patients than in healthy controls (38."( Pharmacokinetics of 51W89: preliminary data.
Boyd, AH; Eastwood, NB; Hunter, JM; Parker, CJ, 1995
)
0.29
" Pharmacokinetic variables were determined using non-compartmental methods."( Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation.
Cook, DR; De Wolf, AM; Freeman, JA; Kerls, S; Kisor, DF; Scott, VL; Smith, DA; Tullock, W, 1996
)
0.29
" Using the NONMEM program, a single compartment pharmacokinetic model was fitted to the plasma concentrations of cis-atracurium and the cis-cis, cis-trans and trans-trans isomers of atracurium."( Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit.
Boyd, AH; Eastwood, NB; Hunter, JM; Parker, CJ, 1996
)
0.29
"min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34."( A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients.
Hunter, JM; Parker, CJ; Smith, CE; van Miert, MM, 1997
)
0.3
" This method has been used to determine the pharmacokinetic profile of atracurium and laudanosine in patients with acute respiratory distress syndrome."( High-performance liquid chromatographic method for the determination of atracurium and laudanosine in human plasma. Application to pharmacokinetics.
Audran, M; Bressolle, F; Farenc, C; Lefrant, JY; Mazerm, I, 1999
)
0.75
" A preliminary independent analysis was done to estimate the individual pharmacokinetic parameters; data were consistent with a one-compartment model."( Pharmacokinetic-pharmacodynamic modeling of atracurium in intensive care patients.
Audran, M; Bressolle, F; Farenc, C; Lefrant, JY, 2001
)
0.31
" The pharmacokinetic variables observed in these severely ill patients were similar to those of anesthetized patients."( The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome.
Cerf, C; Dhonneur, G; Duvaldestin, P; Gillotin, C; Lagneau, F; Mantz, J, 2001
)
0.31
" The mean terminal half-life (t1/2) for atracurium was 18."( Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation.
Bion, JF; Bowden, MI; Chow, B; Ho, E; Weatherley, BC, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency2.85990.044717.8581100.0000AID485294; AID485341
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
acid sphingomyelinaseHomo sapiens (human)Potency19.952614.125424.061339.8107AID504937
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency20.73290.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
mitogen-activated protein kinase 1Homo sapiens (human)Potency10.00000.039816.784239.8107AID995
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
lamin isoform A-delta10Homo sapiens (human)Potency0.01780.891312.067628.1838AID1487
Guanine nucleotide-binding protein GHomo sapiens (human)Potency0.89131.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuronal acetylcholine receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00300.77706.0000AID1489907
Neuronal acetylcholine receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki100.00000.00000.352210.0000AID1489903
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki100.00000.00000.12345.5000AID1489901; AID1489902
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Ki100.00000.00000.10825.5000AID1489901
Neuronal acetylcholine receptor subunit beta-4Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00300.88696.0000AID1489907
Neuronal acetylcholine receptor subunit beta-4Rattus norvegicus (Norway rat)Ki100.00000.00000.296310.0000AID1489902; AID1489903
Neuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)IC50 (µMol)100.00000.00204.15279.9000AID1489909
Neuronal acetylcholine receptor subunit beta-4Mus musculus (house mouse)IC50 (µMol)100.00000.00400.60201.2000AID1489908
Neuronal acetylcholine receptor subunit beta-2Mus musculus (house mouse)IC50 (µMol)100.00000.00400.60201.2000AID1489908
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)EC50 (µMol)100.00000.12802.80188.9000AID1489910
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (43)

Processvia Protein(s)Taxonomy
negative regulation of tumor necrosis factor productionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of protein phosphorylationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
intracellular calcium ion homeostasisNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
learning or memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
short-term memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of cell population proliferationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
negative regulation of tumor necrosis factor productionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of MAPK cascadeNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of angiogenesisNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synapse organizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
sensory processingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of protein metabolic processNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
dendritic spine organizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
modulation of excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
dendrite arborizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of long-term synaptic potentiationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of amyloid-beta formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
negative regulation of amyloid-beta formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of amyloid precursor protein catabolic processNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to amyloid-betaNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of amyloid fibril formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of CoA-transferase activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
amyloid-beta bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
toxic substance bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
chloride channel regulator activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein homodimerization activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
plasma membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
postsynapseNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID332049Inhibition of apamin-sensitive SK channel2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Bis-tetrahydroisoquinoline derivatives: AG525E1, a new step in the search for non-quaternary non-peptidic small conductance Ca(2+)-activated K(+) channel blockers.
AID1134342Toxicity in Swiss albino mouse assessed as ataxia at 100 mg/kg, sc measured up to 20 mins1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Isoquinolines. 5. Synthesis and antiarrhythmic activity of benzylisoquinoline derivatives.
AID1489908Antagonist activity at mouse alpha4beta2 nAChR expressed in HEK293 cells assessed as inhibition of (S)-nicotine-induced current response measured up to 90 secs by FMP assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Dual Nicotinic Acetylcholine Receptor α4β2 Antagonists/α7 Agonists: Synthesis, Docking Studies, and Pharmacological Evaluation of Tetrahydroisoquinolines and Tetrahydroisoquinolinium Salts.
AID1489907Antagonist activity at rat alpha3beta4 nAChR expressed in HEK293 cells assessed as inhibition of (S)-nicotine-induced current response measured up to 90 secs by FMP assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Dual Nicotinic Acetylcholine Receptor α4β2 Antagonists/α7 Agonists: Synthesis, Docking Studies, and Pharmacological Evaluation of Tetrahydroisoquinolines and Tetrahydroisoquinolinium Salts.
AID1489903Displacement of [3H]epibatidine from rat alpha3beta4 nAChR expressed in HEK293 cell membranes after 4 hrs by scintillation counting method2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Dual Nicotinic Acetylcholine Receptor α4β2 Antagonists/α7 Agonists: Synthesis, Docking Studies, and Pharmacological Evaluation of Tetrahydroisoquinolines and Tetrahydroisoquinolinium Salts.
AID1489901Displacement of [3H]epibatidine from rat alpha4beta2 nAChR expressed in HEK293 cell membranes after 4 hrs by scintillation counting method2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Dual Nicotinic Acetylcholine Receptor α4β2 Antagonists/α7 Agonists: Synthesis, Docking Studies, and Pharmacological Evaluation of Tetrahydroisoquinolines and Tetrahydroisoquinolinium Salts.
AID1134357Toxicity in Swiss albino mouse assessed as loss of righting reflex at 47 mg/kg, sc measured up to 20 mins1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Isoquinolines. 5. Synthesis and antiarrhythmic activity of benzylisoquinoline derivatives.
AID1489909Antagonist activity at human alpha7 nAChR expressed in HEK293 cells co-expressing Ric-3/NACHO assessed as inhibition of ACh-induced calcium mobilization measured up to 90 secs in presence of PNU-120596 by FLIPR assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Dual Nicotinic Acetylcholine Receptor α4β2 Antagonists/α7 Agonists: Synthesis, Docking Studies, and Pharmacological Evaluation of Tetrahydroisoquinolines and Tetrahydroisoquinolinium Salts.
AID1134345Toxicity in Swiss albino mouse assessed as mortality at 100 mg/kg, sc measured up to 20 mins1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Isoquinolines. 5. Synthesis and antiarrhythmic activity of benzylisoquinoline derivatives.
AID1134343Toxicity in Swiss albino mouse assessed as convulsions at 100 mg/kg, sc measured up to 20 mins1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Isoquinolines. 5. Synthesis and antiarrhythmic activity of benzylisoquinoline derivatives.
AID263607Inhibition of AChE at 0.01 mM2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Isoquinoline derivatives as potential acetylcholinesterase inhibitors.
AID377193Antimicrobial activity against Staphylococcus aureus 4222 with norA KLE 820(3) mutation2000Journal of natural products, Aug, Volume: 63, Issue:8
5'-Methoxyhydnocarpin-D and pheophorbide A: Berberis species components that potentiate berberine growth inhibition of resistant Staphylococcus aureus.
AID1134356Toxicity in Swiss albino mouse assessed as ataxia at 47 mg/kg, sc measured up to 20 mins1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Isoquinolines. 5. Synthesis and antiarrhythmic activity of benzylisoquinoline derivatives.
AID1489902Displacement of [3H]epibatidine from rat alpha4beta4 nAChR expressed in HEK293 cell membranes after 4 hrs by scintillation counting method2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Dual Nicotinic Acetylcholine Receptor α4β2 Antagonists/α7 Agonists: Synthesis, Docking Studies, and Pharmacological Evaluation of Tetrahydroisoquinolines and Tetrahydroisoquinolinium Salts.
AID1489910Agonist activity at human alpha7 nAChR expressed in HEK293 cells co-expressing Ric-3/NACHO assessed as induction of calcium mobilization measured up to 90 secs in presence of PNU-120596 by FLIPR assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Dual Nicotinic Acetylcholine Receptor α4β2 Antagonists/α7 Agonists: Synthesis, Docking Studies, and Pharmacological Evaluation of Tetrahydroisoquinolines and Tetrahydroisoquinolinium Salts.
AID1134344Toxicity in Swiss albino mouse assessed as loss of righting reflex at 100 mg/kg, sc measured up to 20 mins1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Isoquinolines. 5. Synthesis and antiarrhythmic activity of benzylisoquinoline derivatives.
AID674573Induction of rat C/EBPalpha expression transfected in human U937 cells at 25 uM after 24 hrs by luciferase reporter gene assay relative to ATRA2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID263606Inhibition of AChE at 0.1 mM2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Isoquinoline derivatives as potential acetylcholinesterase inhibitors.
AID1134340Antiarrhythmic activity in Swiss albino mouse assessed as protection against chloroform-induced ventricular fibrillation at 47 mg/kg, sc administered 20 mins prior to challenge1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Isoquinolines. 5. Synthesis and antiarrhythmic activity of benzylisoquinoline derivatives.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID674572Induction of rat C/EBPalpha expression transfected in human U937 cells after 24 hrs by luciferase reporter gene assay relative to ATRA2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID1134338Antiarrhythmic activity in Swiss albino mouse assessed as protection against chloroform-induced ventricular fibrillation at 100 mg/kg, sc administered 20 mins prior to challenge1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Isoquinolines. 5. Synthesis and antiarrhythmic activity of benzylisoquinoline derivatives.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (130)

TimeframeStudies, This Drug (%)All Drugs %
pre-199037 (28.46)18.7374
1990's47 (36.15)18.2507
2000's22 (16.92)29.6817
2010's23 (17.69)24.3611
2020's1 (0.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.34 (24.57)
Research Supply Index4.96 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index65.76 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (6.77%)5.53%
Reviews5 (3.76%)6.00%
Case Studies10 (7.52%)4.05%
Observational0 (0.00%)0.25%
Other109 (81.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]